Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 71%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is demonstrating a strong positive trajectory due to the attainment of RMAT designation for its lead gene therapy candidate, detalimogene, which enhances its market potential, especially in community practice settings. The company's clinical trial results indicate that detalimogene's six-month complete response (CR) rate aligns with leading therapies while benefiting from a preferable non-viral delivery method, thus expanding its potential addressable market. Additionally, the marked increase in research and development expenditures reflects significant investments in advancing their pivotal LEGEND study, contributing to an elevated discounted cash flow-derived valuation estimate.

Bears say

enGene Holdings Inc faces several challenges that contribute to a negative outlook on its stock. The company is experiencing disappointing performance in its LEGEND trial for detalimogene, alongside unexpected safety issues and changing regulatory requirements that could delay approvals, ultimately impacting investor confidence and share price. Additionally, the heightened competition and anticipated need for further equity financing pose significant financial risks, potentially resulting in dilution for existing shareholders.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 71% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.